OLDWICK, N.J.–(BUSINESS WIRE)– #insurance–AM Best has upgraded the Financial Strength Rating to A- (Excellent) from B++ (Good) and the Long-Term Issuer Credit Rating to “a-” (Excellent) from “bbb+” (Good) of Bupa Insurance Company (BIC) (Palmetto Bay, FL). The outlook of these Credit Ratings (ratings) is stable.The ratings reflect BIC’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile, appropriate enterprise risk managem
Month: September 2026
VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) the Purchased Assets (as defined below) comprising the Meadows Project (the “Project”) located in west-central Saskatchewan near the Alberta border (the “Meadows Project”).
The Meadows Project is represented by Saskatchewan Subsurface Mineral Permit #SMP273 (the “Permit”). Under the Asset Purchase Agreement, the Company will acquire 100% of the Vendor’s interest in the Permit, all transferable technical information relating to the Meadows Project and all transferable governmental authorizations relating to the Permit (collectively, the “Purchased Assets”).
Transaction Terms
The purchase price for the Purchased Assets is C$255,000, payable in cash by the Company to the Vendor at closing. Upon closing, the Company will assume only those obligations that, as a matter of applicable law must accompany the Permit including an annual rental rate of approximately $43,219 during Permit years one through five and approximately $108,047 during Permit years six through eight, and a work commitment of approximately $9.81 million over the next eight years, commencing July 14, 2026. Except for such assumed obligations, the Company will not assume any liabilities of the Vendor.
The Transaction is expected to close on or about October 1, 2026, subject to the satisfaction or waiver of customary closing conditions set out in the Asset Purchase Agreement.
Completion of the Transaction remains subject to customary closing conditions, including receipt of all required governmental, regulatory and third-party approvals and consents, approval and registration of the transfer of the Permit, delivery of customary closing documents, the accuracy of the parties’ representations and warranties, performance of their respective covenants, and the Purchased Assets being transferred free and clear of all encumbrances, except for permitted encumbrances. There can be no assurance that the Transaction will be completed on the terms contemplated in the Asset Purchase Agreement or at all.
Project Highlights
The Meadows Project comprises approximately 21,609 hectares across 338 Crown parcels in northwestern Saskatchewan, near the Alberta border. The Permit covers Crown subsurface mineral rights within the Elk Point Group, a geological succession containing thick salt-bearing intervals documented in historical wells surrounding the Project. This regional evidence provides an encouraging basis to explore the Project for salt with potential applications for compressed air energy storage and hydrogen storage. Nearby Cold Lake provides an established energy-industry and regional service centre, while Highway 919 and regional resource roads provide potential access to the Project, with Meadow Lake serving as a regional logistics centre. The presence, thickness, continuity and quality of salt beneath the Permit, and its suitability for cavern development, remain unconfirmed. Further exploration and technical work will be required to evaluate the Project’s potential.
Qualified Person
The scientific and technical information regarding the Meadows Project contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo. (APEGS #36165), Vice President of Exploration at Vortex, a “qualified person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.
About Vortex Energy Corp.
Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 linear kms south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.
On Behalf of the Board of Directors
Paul Sparkes
Chief Executive Officer, Director
+1 (778) 819-0164
info@vortexenergycorp.com
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking information relates to future events or future performance and is often, but not always, identified by words such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “may”, “will”, “could” and similar expressions. All statements other than statements of historical fact may be forward-looking information.
Forward-looking information in this press release includes statements regarding the anticipated completion and timing of the Transaction; the satisfaction or waiver of the conditions to closing; the receipt of required approvals and consents; and the approval and registration of the transfer of the Permit. Such forward-looking information is based on assumptions considered reasonable by management as of the date of this press release, including that the parties will satisfy or waive the applicable closing conditions, obtain the required approvals and consents, complete and register the transfer of the Permit, and complete the Transaction on the terms and timeline contemplated by the Asset Purchase Agreement.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied, including the risks that the closing conditions may not be satisfied or waived; required approvals or consents may not be obtained; the transfer of the Permit may not be approved or registered; the Transaction may be delayed, may not close on the expected terms or timeline, or may not close at all; and other risks inherent in mineral property acquisitions and the Company’s business. There can be no assurance that forward-looking information will prove to be accurate. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and the Company undertakes no obligation to update or revise it, except as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
LOUISVILLE, Ky.–(BUSINESS WIRE)–Brown-Forman Corporation (NYSE: BFA, BFB) today announced the pricing of a $500 million 5-year senior unsecured note. The 5.375% 5-year senior notes are due October 15, 2031. Brown-Forman intends to use the net proceeds from the offering for general corporate purposes, which may include dividends, repurchases of stock by the company pursuant to any authorized stock repurchase program or otherwise, repaying, redeeming, or repurchasing existing debt, including co
EDMONTON, AB–(BUSINESS WIRE)–“CUPE Alberta is deeply concerned about the upcoming referendum and its possible implications for our members, particularly those who are racialized and/or newcomers to Alberta,” says CUPE Alberta President Raj Uppal. “In the coming weeks, we will be working to ensure our members understand what is at stake. We have launched a website https://NoToScapegoating.ca/ that provides information and resources to our locals and members, complete with a guide for members t
NEW YORK–(BUSINESS WIRE)– #creditratingagency–KBRA releases research examining the credit implications of the meaningful shift in property-catastrophe reinsurance pricing and terms in favor of property and casualty (P&C) insurers. Abundant traditional and alternative capital, strong reinsurer balance sheets, and increased competition have contributed to declining pricing and improved terms through the 2026 renewal season, after several years of rising reinsurance costs, constrained capacity, and higher attach
SACRAMENTO, Calif.–(BUSINESS WIRE)–Following Governor Gavin Newsom’s announcement of the new Disaster Rebuilding Assistance Program, CalHFA, the state agency administering the program, released program details. “Many families are still navigating the challenges and trauma that follow the loss of a home,” said CalHFA Executive Director Tony Sertich. “The state is here to support their recovery and help them rebuild their homes and communities.” As more disaster survivors are transitioning from
NEW YORK–(BUSINESS WIRE)–Rithm Capital Corp. (NYSE: RITM, “Rithm” or the “Company”), a global alternative asset manager, today announced that Ann DeVries has joined the firm as Head of Investor Relations. In this role, Ms. DeVries will lead the development and execution of Rithm’s investor relations strategy, overseeing engagement with current and prospective shareholders and the sell-side analyst community. Working closely with senior leadership and teams across the platform, she will commun
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lapiplasty®, the MTA3D® Adductoplasty® and the SPRINT™ SpeedPlate® clinical studies.
“We are proud to present a robust body of clinical evidence at AOFAS 2026 that continues to reinforce the durability and clinical value of our flagship procedures and technologies,” said John T. Treace, CEO, Founder and Chairman of Treace. “The 5-year ALIGN3D® data represents a first-in-industry milestone, demonstrating sustained, positive outcomes following the Lapiplasty® Procedure. Complementing this are our 2-year MTA3D® interim results and SPRINT™ study results that further validate our technologies. Together, these studies underscore our commitment to generating high-quality, prospective clinical evidence that differentiates our technologies and supports better outcomes for patients.”
ALIGN3D® 5-Year Lapiplasty® Clinical Study Results
The ALIGN3D™ Lapiplasty® clinical study podium presentation, “Five-Year Analysis of a Prospective Multicenter Study of Triplanar Tarsometatarsal Arthrodesis With Early Weightbearing: Radiographic, Clinical and Patient Reported Outcomes”, to be presented by Daniel Farber, MD, Lehigh Valley Orthopedic Institute (Bethlehem, PA).
Featured data from the study included final analysis of 137 of 173 total patients treated with five years of follow-up following the Lapiplasty® Procedure. The data showed:
- Early return to weight bearing in a walking boot at an average 8.4 days;
- Low radiographic recurrence rates of 0.8% using HVA>20° and 5.3% using HVA>15° at 5 years; and
- Clinically significant reduction in patient-reported scores (MOxFQ and PROMIS) through 5 years.
MTA3D® Adductoplasty® Clinical Study Results
The MTA3D® Adductoplasty® clinical study podium presentation, “Radiographic and Patient-Reported Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction with Early Weightbearing – 2-year Interim Results of a Multicenter Prospective Study”, presented by Mark Easley, MD, Duke University (Durham, NC).
The featured interim data from the study of patients undergoing both the Adductoplasty® and Lapiplasty® procedures included interim analysis of 59 of 66 and 35 of 66 patients treated with at least one- and two-year follow-up, respectively. The data showed:
- Early return to weight bearing in a walking boot at an average 7.6 days;
- Clinically significant improvement and maintenance of radiographic measures of both midfoot (metatarsus adductus) and 3D bunion correction through 24 months; and
- Clinically significant reduction in pain and patient-reported scores (VAS, MOxFQ, and PROMIS) through 24 months.
SPRINT™ SpeedPlate® Observational Study Results
The SPRINT™ SpeedPlate® observational clinical study audio poster presentation, “Radiographic and Patient-Reported Outcomes Following Joint Arthrodesis in the Foot Using a Novel, Dynamic Compression Implant System”, presented by Jody McAleer, DPM, Jefferson City Medical Group (Jefferson City, MO).
Featured data from the one-year, multicenter study included final analysis of 89 of 91 total patients following MTP and/or TMT joint arthrodesis using SpeedPlate® Rapid Compression Implants. The data showed:
- Early return to weight bearing in a walking boot at an average 9.0 days;
- High union rates with clinical and radiographic healing in 96.6% of patients at 12 months; and
- Clinically significant improvements in radiographic correction (HVA, IMA, TSP, Osseous Foot Width) at 6 weeks and maintained through 12 months in patients with hallux valgus.
All AOFAS presentations, which include additional details such as patient demographics, inclusion/exclusion criteria, and complications reported in the studies, will be available on Treace’s website at https://www.treace.com/resources/journal-publications/ following their presentations at ACFAS. More information on Treace’s products can be found at www.treace.com.
About the ALIGN3D™ Clinical Study
The ALIGN3D™ clinical study is a prospective, multicenter, post-market clinical study designed to evaluate outcomes of the Lapiplasty® 3D Bunion Correction® procedure in the surgical management of symptomatic hallux valgus. The study evaluates consistency and reliability of correction of all three dimensions of the bunion deformity with the Lapiplasty® Procedure, as well as maintenance of such correction following accelerated return to weight-bearing, initially in a walking boot. The primary effectiveness endpoint is radiographic recurrence of the hallux valgus deformity. Key secondary endpoints include change in three-dimensional radiographic alignment; clinical radiographic healing; time to start of weight-bearing in a boot and in shoes; pain; quality of life; and range of motion of the big toe joint. The study enrolled 173 patients, aged 14 to 58 years, at 7 clinical sites in the United States with 13 participating surgeons. Final patient follow-up for the primary endpoint was completed in the first half of 2023, and study completion with 5-year data was completed in 2026.
About the MTA3D® Clinical Study
The MTA3D® clinical study is a prospective, multicenter, post-market study designed to evaluate the combined Adductoplasty® and Lapiplasty® Procedures for patients in need of metatarsus adductus and hallux valgus corrective surgery. The study will evaluate for consistent, maintained radiographic correction and patient-reported outcome scores following combined Adductoplasty® and Lapiplasty® procedures. The primary effectiveness endpoint is maintenance of radiographic correction of the hallux valgus and metatarsus adductus deformities. Key secondary endpoints include clinical radiographic healing, time to start weight-bearing in a boot and shoes; pain; quality of life; and range of motion of the big toe joint. The study treated up to 66 patients, aged 14 years and up, at 7 clinical sites in the United States. Patients will be followed for 2 years following the procedures.
About the SPRINT™ Observational Study
The SPRINT™ clinical study is an ambirectional, multicenter, post-market study designed to evaluate the healing/union rates following joint fixation using the SpeedPlate® Rapid Compression Implants and whether early weight-bearing following joint fixation affects the healing/union rates. The primary effectiveness endpoint is clinical/radiographic healing rates at 12 months. Key secondary endpoints include change in three-dimensional radiographic alignment; time to start of weight-bearing in a boot and in shoes; pain; and patient satisfaction. The study included 91 treated patients, aged 14 years and up, at 5 clinical sites in the United States. Patients were followed for 1 year following the procedure.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty® Percutaneous 3D Bunion Correction System, and the SpeedMTP® 1st MTP Fusion System for bunions treated through great toe fusions. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology, and offering SuperBite™ Fully-Threaded Compression Screws for use in fusions throughout the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
NEW YORK–(BUSINESS WIRE)–Stensul, the Governed Creation™ Platform for enterprise marketing, today announced the beta availability of an integration with Marketing Cloud Next, building on its longstanding support for Salesforce. The new integration gives enterprise marketing teams and AI agents a governed way to create and personalize email campaigns using Salesforce audiences and data, without exposing underlying customer information to campaign builders. Teams can assemble campaign content a
LINKÖPING, Zweden–(BUSINESS WIRE)–De beoordeling voor 2026 bouwt voort op de eerste opname van AMRA in de ranglijst van 2025, toen het bedrijf de kwalificatie ‘Very High’ kreeg. De promotie naar de hoogste categorie weerspiegelt de aanhoudende vooruitgang op het vlak van wetenschappelijke excellentie en technologische innovatie, evenals de toenemende toepassing van op MRI gebaseerde biomarkers in onderzoek, geneesmiddelenontwikkeling en klinische zorg. “Dat we voor het tweede opeenvolgende ja